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SUPPLEMENTARY MATERIALS
Tissue biodistribution and tumor targeting of near-infrared labelled 
anti-CD38 antibody-drug conjugate in preclinical multiple myeloma
Supplementary Figure 1: Analytical characterization of DARA-DM1 and DARA-DM1-IR. (A) Representative mass 
spectrometry spectra and percent distribution of DARA with 1, 2, 3, 4 or 5+ DM1 drugs per antibody at a 20 to 1 conjugation ratio. (B) 
Antibody-dye absorbance spectra of DARA-DM1-IR and DARA-IR. After reaction and purification, the absorbance spectrum for DARA-
DM1-IR and DARA-IR were used to determine the DoL as described in the methods section. DoL was determined by dividing bulk 
fluorophore concentration by antibody concentration. (C) Fluorescence emission spectra of DARA-DM1-IR and DARA-IR.
Supplementary Figure 2: In vitro stability of DARA-DM1-IR and DARA-IR. SDS-PAGE of DARA-DM1-IR and DARA-IR 
incubated in PBS and human serum between 1 and 7 days. 
Supplementary Figure 3: Internalization of DARA conjugates. Flow cytometric analysis of percent of MM.1S and U266 cells 
internalized with DARA-IR and DARA-DM1-IR in LAMP-1+ lysosomes 3 hours post-incubation. Student t-tests were performed for each 
conjugate and cell line. ****p < 0.0001. Error bars represent standard deviation. 
Supplementary Figure 4: Body weights of untreated and treated MM.1S IV mice. Mean body weights of MM.1S IV mice 
following treatment with DARA or DARA-DM1. Error bars represent standard deviation.
